Gilead Sciences Announces Changes to Senior Leadership Team
July 17 2019 - 8:30AM
Business Wire
Gilead Sciences, Inc. (Nasdaq: GILD) announced today changes to
the company’s senior leadership team. Gregg Alton, Chief Patient
Officer, and Katie Watson, Executive Vice President, Human
Resources, will be departing Gilead. Jyoti Mehra has been named
Executive Vice President, Human Resources, and will assume
responsibility for the worldwide HR function.
Mr. Alton joined Gilead in 1999 and most recently has led
Gilead’s corporate and medical affairs functions and developing
world access programs, as well as commercial operations in certain
countries of Asia and Latin America. He previously served as
general counsel and helped to architect the company’s innovative
access model for HIV and viral hepatitis medicines in
resource-limited countries. He will remain with Gilead through
October 4 and plans to serve in an advisory capacity until the end
of the year to help transition his responsibilities to other parts
of the organization.
“Gregg has been a valued leader at Gilead for nearly 20 years,”
said Daniel O’Day, Chairman and Chief Executive Officer of Gilead.
“His unwavering focus on enabling and expanding access to medicines
has allowed the company to help millions of individuals in
countries most heavily impacted by HIV, hepatitis B and hepatitis
C. I want to thank Gregg for his many contributions and tireless
advocacy.”
“I am honored to have had the opportunity to help lead Gilead
for nearly two decades,” said Mr. Alton. “On behalf of the
organizations I have had a chance to lead, I am extraordinarily
proud of the work we have done together to drive innovative
solutions to reach the people most in need of our medications
around the world.”
Ms. Watson joined Gilead in 2003 and during her 16 years with
the company has helped to support significant organizational growth
around the world. She has been responsible for attracting,
developing and retaining talent, and delivering a strategic
approach to engaging the company’s employees. She has helped to
foster a culture that builds on Gilead’s core values of inclusion,
teamwork, excellence, accountability and integrity.
“Katie has had a tremendous impact on Gilead, and I would like
to thank her for her many contributions, including her dedication
to improving the experience for the more than 11,000 employees at
our company,” commented Mr. O’Day. “It is a testament to her
leadership and her skill in developing people that we were quickly
able to identify a strong successor. I know Jyoti will build on the
important work underway to ensure Gilead is considered among the
best places to work in our industry.”
“Helping Gilead grow and hire so many talented individuals and
working to develop and retain our employees has been a privilege
for the past 16 years,” commented Ms. Watson. “I am deeply
appreciative of the opportunity to be a part of a company that has
transformed care for patients, and I am confident our HR
organization will continue contributing to this mission.”
Effective August 5, Ms. Mehra will be appointed as Ms. Watson’s
successor. Ms. Watson will depart Gilead on September 1, remaining
with Gilead in an advisory capacity through the end of the year to
ensure a smooth transition. Ms. Mehra joined Gilead in 2017 as Vice
President, Human Resources. She has more than 20 years of
experience building organizational capabilities and shaping
high-performing teams and cultures. She has worked across the
United States, Europe and Asia. Prior to joining Gilead, she held
positions of increasing seniority at Novartis Pharmaceuticals Corp.
and Eli Lilly & Co.
“It is a great privilege to take on this role and to lead
Gilead’s Human Resources organization,” said Ms. Mehra. “As a
company, Gilead has enjoyed tremendous success because of the smart
and talented people who work here. It is truly an honor to have the
opportunity to continue to shape Gilead’s culture in this position
and to build on the company’s strong past by adding organizational
capabilities.”
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical
company that discovers, develops and commercializes innovative
medicines in areas of unmet medical need. The company strives to
transform and simplify care for people with life-threatening
illnesses around the world. Gilead has operations in more than 35
countries worldwide, with headquarters in Foster City,
California.
For more information about Gilead, please visit
the company’s website at www.gilead.com, follow Gilead on Twitter
(@GileadSciences) or call Gilead Public Affairs at 1 800-GILEAD-5
or 1-650-574-3000.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190717005229/en/
Sung Lee, Investors (650) 524-7792 Amy Flood, Media (650)
522-5643
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024